LifeStance Health Group (NASDAQ:LFST) Price Target Raised to $7.00

LifeStance Health Group (NASDAQ:LFST) had its target price increased by Barclays from $6.00 to $7.00 in a research report released on Monday,Benzinga reports. The firm currently has an underweight rating on the stock.

Separately, UBS Group decreased their price target on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating for the company in a research note on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $8.42.

LifeStance Health Group Price Performance

Shares of LFST opened at $7.39 on Monday. The company has a market cap of $2.83 billion, a P/E ratio of -28.42 and a beta of 1.24. The stock has a fifty day moving average price of $6.94 and a 200 day moving average price of $6.22. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.22 and a quick ratio of 1.22. LifeStance Health Group has a 12 month low of $4.64 and a 12 month high of $9.20.

LifeStance Health Group (NASDAQ:LFST) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. LifeStance Health Group had a negative return on equity of 6.67% and a negative net margin of 7.90%. The company had revenue of $312.70 million during the quarter, compared to analysts’ expectations of $302.25 million. During the same quarter in the prior year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 18.9% compared to the same quarter last year. On average, research analysts forecast that LifeStance Health Group will post -0.22 earnings per share for the current year.

Insider Activity

In other news, insider Ann Varanakis sold 5,269 shares of the company’s stock in a transaction on Friday, August 23rd. The stock was sold at an average price of $6.28, for a total value of $33,089.32. Following the completion of the sale, the insider now owns 263,007 shares in the company, valued at $1,651,683.96. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

Several hedge funds have recently modified their holdings of LFST. CIBC Asset Management Inc purchased a new stake in shares of LifeStance Health Group during the second quarter valued at $53,000. Bessemer Group Inc. lifted its holdings in shares of LifeStance Health Group by 43.4% during the 1st quarter. Bessemer Group Inc. now owns 9,143 shares of the company’s stock valued at $56,000 after buying an additional 2,768 shares during the last quarter. Algert Global LLC acquired a new stake in shares of LifeStance Health Group during the 2nd quarter valued at about $57,000. Victory Capital Management Inc. raised its stake in shares of LifeStance Health Group by 27.0% in the 2nd quarter. Victory Capital Management Inc. now owns 14,407 shares of the company’s stock valued at $71,000 after acquiring an additional 3,063 shares in the last quarter. Finally, Park Edge Advisors LLC bought a new position in shares of LifeStance Health Group in the 3rd quarter valued at approximately $73,000. 85.50% of the stock is owned by hedge funds and other institutional investors.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.